Breaking News

Baxter BioScience Names R&D VP

July 10, 2014

Orloff to head pipeline innovation

John Orloff, M.D., has been appointed vice president and global head of R&D for Baxter BioScience. Dr. Orloff will be responsible for advancing the late-stage BioScience pipeline, enhancing the current R&D operating model and pursuing additional opportunities for the business.
 
Dr. Orloff joins the company from Merck Serono Pharmaceuticals, where he served as global head of clinical development. Previously, he spent 10 years at Novartis, where he served various roles of increasing responsibility, including chief medical officer for global development. Dr. Orloff also supported clinical development at Merck Research Labs. Dr. Orloff brings expertise in bone biology, and has led programs across a range of therapeutic areas, including immunology, neurology and oncology.
 
“As we work toward becoming an independent global biopharmaceutical company, our priorities are to drive innovation by advancing our rich, late-stage development pipeline, expanding our expertise in immunology, hematology, and other core technologies and optimizing our R&D productivity,” said Ludwig Hantson, Ph.D., president of Baxter BioScience. “John brings significant scientific and leadership expertise, including preclinical research, clinical development, and medical and regulatory affairs. He will be a valuable member of our executive leadership team and a guiding force for effectively executing the development strategy for our organization.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016